Nano-Based Co-Delivery System for Treatment of Rheumatoid Arthritis

Molecules. 2022 Sep 14;27(18):5973. doi: 10.3390/molecules27185973.

Abstract

A systemic autoimmune condition known as rheumatoid arthritis (RA) has a significant impact on patients' quality of life. Given the complexity of RA's biology, no single treatment can totally block the disease's progression. The combined use of co-delivery regimens integrating various diverse mechanisms has been widely acknowledged as a way to make up for the drawbacks of single therapy. These days, co-delivery systems have been frequently utilized for co-treatment, getting over drug limitations, imaging of inflammatory areas, and inducing reactions. Various small molecules, nucleic acid drugs, and enzyme-like agents intended for co-delivery are frequently capable of producing the ability to require positive outcomes. In addition, the excellent response effect of phototherapeutic agents has led to their frequent use for delivery together with chemotherapeutics. In this review, we discuss different types of nano-based co-delivery systems and their advantages, limitations, and future directions. In addition, we review the prospects and predicted challenges for the combining of phototherapeutic agents with conventional drugs, hoping to provide some theoretical support for future in-depth studies of nano-based co-delivery systems and phototherapeutic agents.

Keywords: co-delivery system; combination therapy; drug delivery; nanoparticles; phototherapy; rheumatoid arthritis (RA).

Publication types

  • Review

MeSH terms

  • Arthritis, Rheumatoid* / drug therapy
  • Drug Delivery Systems
  • Humans
  • Nanoparticle Drug Delivery System
  • Nucleic Acids* / therapeutic use
  • Quality of Life

Substances

  • Nanoparticle Drug Delivery System
  • Nucleic Acids

Grants and funding

This stuudy was supported by Jilin Province Science and Technology Development Program (No.20220402036GH).